Ayrton Saunders Announces Landmark UK MHRA Approval of Next Generation Nicotine Inhaler System for Rapid, Safe Relief of Nicotine Craving to Aid Smoking Cessation
25 juin 2024 03h00 HE
|
OBG Pharma
Becomes the world's first and only clinically approved nicotine inhaler enabling rapid absorption via the lungs to help smokers replace, cut down, and ultimately quit smokingAs a General Sales List...
$53.8+ Billion Smoking Cessation & Nicotine De-Addiction Product Market Report, 2024-2030: Business Opportunities for Drug Therapy, E-Cigarettes, and Nicotine Inhalers
21 juin 2024 09h18 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Smoking Cessation & Nicotine De-Addiction Product Market 2024-2030" report has been added to ResearchAndMarkets.com's offering.The Smoking...
United States Health Coaching Market Outlook & Forecasts 2024-2029: Growing Focus on Corporate Wellness, Advancements & New Initiatives, Growing Preference for Online and Digital Platforms
13 juin 2024 11h41 HE
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "U.S. Health Coaching Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.The U.S. Health...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
29 mai 2024 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global...
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
09 mai 2024 16h01 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and...
Smoking Cessation and Nicotine Deaddiction Landscape Report 2024: Therapeutic Assessment of Novel Drug Candidates, Emerging Drugs and the Route to Commercialization
12 avr. 2024 10h04 HE
|
Research and Markets
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The global commitment...
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
11 avr. 2024 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
20 mars 2024 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Smoking Cessation and Nicotine De-Addiction Market to Reach USD 27.84 billion by 2031, at a CAGR of 10.2% - Transparency Market Research, Inc.
11 mars 2024 07h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 11, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global smoking cessation and nicotine de-addiction market is estimated to flourish at a...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
06 mars 2024 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...